Market for TMB, MSI / MMR and TILs is projected to grow at an annualized rate of ~

Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opport...
Roots Analysis has done a detailed study on Cancer Biomarkers Market: Focus on TMB, MSI / MMR and TILs Testing, 2019-2030, covering key aspects of the industry and identifying key future growth opportunities.   To order this 370+ page report, which features 190+ figures and 180+ tables, please visit this link   Key Market Insights   For more information, please visit https://www.rootsanalysis.com/reports/view_document/cancer-biomarkers-market-focus-on-tmb-msi--mmr-and-tils-testing-2019--2030/253.html   Table of Contents   1.1.       Scope of the Report 1.2.       Research Methodology 1.3.       Chapter Outlines     3.1.
      Chapter Overview 3.2.       Cancer Immunotherapy 3.2.1.    Cancer Immunotherapy Biomarkers 3.2.2.    Identification of a Candidate Biomarker 3.2.3.    Need for Novel Cancer Biomarkers   3.3.       Tumor Mutation Burden (TMB) 3.3.1.    Overview 3.3.2.    Variation of TMB across Multiple Indications 3.3.3.    Methods for Measurement of TMB 3.3.4.    Factors Affecting Measurement of TMB 3.3.5.    Initiatives for Assessment of TMB as a Potential Biomarker   3.4.       Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR) 3.4.1.    Overview 3.4.2.    Variation of MSI across Multiple Indications 3.4.3.    Methods of Measurement of MSI   3.5.       Tumor Infiltrating Lymphocytes and Other Novel Biomarkers   4          CURRENT MARKET LANDSCAPE 4.1.       Chapter Overview 4.2.       Cancer Biomarkers Testing Services: Overall Market Landscape 4.2.1.    Analysis by Year of Establishment 4.2.2.    Analysis by Company Size 4.2.3.    Analysis by Geographical Location 4.2.4.    Analysis by Test Availability 4.2.5.    Analysis by Type of Biomarker 4.2.6.    Analysis by Application Area 4.2.7.    Analysis by Disease Indication 4.2.8.    Analysis by Analytical Technique Used 4.2.9.    Analysis by Turnaround Time 4.2.10.  Analysis by Sample Input 4.2.11.  Analysis by Nucleic Acid Tested 4.2.12.  Key Players: Analysis by Type of Biomarker   4.3.       TMB Tests 4.3.1.    Analysis by Application Area 4.3.2.    Analysis by Disease Indication 4.3.3.    Analysis by Analytical Technique Used 4.3.4.    Analysis by Turnaround Time   4.4.       MSI / MMR Tests 4.4.1.    Analysis by Application Area 4.4.2.    Analysis by Disease Indication 4.4.3.    Analysis by Analytical Technique Used 4.4.4.    Analysis by Turnaround Time   4.5.       TIL-based Tests 4.5.1.    Analysis by Application Area 4.5.2.    Analysis by Disease Indication 4.5.3.    Analysis by Analytical Technique Used 4.5.4.    Analysis by Turnaround Time   5          PRODUCT COMPETITIVENESS ANALYSIS 5.1.       Chapter Overview 5.2.       Product Competitiveness Analysis: Key Assumptions and Methodology 5.2.1.    Tests for the Assessment of TMB 5.2.2.    Tests for the Assessment of MSI / MMR 5.2.3.    Tests for the Assessment of TILs   6          COMPANY PROFILES  6.1.       Chapter Overview 6.2.       Dr Lal PathLabs 6.2.1.    Company Overview       6.2.2.    Financial Information     6.2.3.    Product / Service Portfolio         6.2.3.1.
Biomarkers Testing Portfolio      6.2.3.1.1. Microsatellite Instability (MSI) by PCR  6.2.3.1.2.
OncoPro NCCN Lung Cancer Panel (*9 Genes *MSI)   6.2.3.1.3. OncoPro Liquid Biopsy 73 Gene Panel with MSI           6.2.4.    Recent Developments and Future Outlook            6.3.       Foundation Medicine     6.3.1.    Company Overview       6.3.2.    Financial Information     6.3.3.    Product / Service Portfolio         6.3.3.1.
Biomarkers Testing Portfolio      6.3.3.1.1. FoundationOne CDx   6.3.3.1.2.
FoundationOne Liquid 6.3.3.1.3. FoundationOne Heme 6.3.4.    Recent Developments and Future Outlook                      6.4.       NeoGenomics Laboratories        6.4.1.    Company Overview       6.4.2.    Financial Information     6.4.3.    Product / Service Portfolio         6.4.3.1.
Biomarkers Testing Portfolio      6.4.3.1.1. NeoTYPE Discovery Profile for Solid Tumors   6.4.3.1.2.
MSI Analysis / MMR Panel by IHC       6.4.3.1.3. MultiOmyx Tumor Infiltrating Lymphocyte Panel           6.4.4.    Recent Developments and Future Outlook            6.5.       Novogene         6.5.1.    Company Overview       6.5.2.    Product / Service Portfolio         6.5.2.1.
Biomarkers Testing Portfolio      6.5.2.1.1. NovoPM Cancer Panel            6.5.2.1.2.
NovoPM TMB 6.5.2.1.3. NovoPM bTMB 6.5.2.1.4.
NovoPM MSI 6.5.3.    Recent Developments and Future Outlook   6.6.       Q2 Solutions     6.6.1.    Company Overview       6.6.2.    Product / Service Portfolio         6.6.2.1. Biomarkers Testing Portfolio      6.6.2.1.1.
TMB Assay    6.6.2.1.2. MSI Assay     6.6.2.1.3.
TILs Testing   6.6.3.    Recent Developments and Future Outlook             6.7.       Personal Genome Diagnostics   6.7.1.    Company Overview       6.7.2.    Product / Service Portfolio         6.7.2.1. Biomarkers Testing Portfolio      6.7.2.1.1.
PGDx elio Tissue Complete Assay      6.7.2.1.2. PlasmaSELECT-R 64 6.7.2.1.3.
CancerXOME-R          6.7.2.1.4. CancerSELECT-R 125            6.7.2.1.5.
MutatorDETECT         6.7.3.    Recent Developments and Future Outlook            6.8.       Shenzhen Yuce Biotechnology  6.8.1.    Company Overview       6.8.2.    Product / Service Portfolio         6.8.2.1. Biomarkers Testing Portfolio      6.8.2.1.1.
YuceOne Plus            6.8.2.1.2. YuceOne ICIs 6.8.2.1.3.
ct-DNA TMB   6.8.2.1.4. Microsatellite (MSI) Test          6.8.3.    Recent Developments and Future Outlook             7          PUBLICATION ANALYSIS 7.1.       Chapter Overview 7.2.       Methodology 7.3.       Cancer Biomarkers: List of Publications 7.3.1.    Analysis by Year of Publication, 2016-2019 7.3.2.    Analysis by Year of Publication and Type of Biomarker 7.3.3.    Analysis by Year of Publication and Disease Indication 7.3.4.    Analysis by Year of Publication and Analytical Technique Used 7.3.5.    Analysis by Year of Publication and Type of Cancer Therapy 7.3.6.    Most Popular Journals   7.4.       Publication Analysis: TMB 7.4.1.    Analysis by Year of Publication, 2016-2019 7.4.2.    Analysis by Disease Indication 7.4.3.    Analysis by Analytical Technique Used 7.4.4.    Most Popular Journals   7.5.       Publication Analysis: MSI / MMR 7.5.1.    Analysis by Year of Publication, 2016-2019 7.5.2.    Analysis by Disease Indication 7.5.3.    Analysis by Analytical Technique Used 7.5.4.    Most Popular Journals   7.6.       Publication Analysis: TILs 7.6.1.    Analysis by Year of Publication, 2016-2019 7.6.2.    Analysis by Disease Indication 7.6.3.    Analysis by Analytical Technique Used 7.6.4.    Most Popular Journals   8          INNOVATIVE DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS 8.1.       Background and Context 8.2.       Biomarker-based Clinical Trial Designs 8.2.1.    Enrichment Design 8.2.2.    All-Comers Design 8.2.3.    Mixture / Hybrid Design 8.2.4.    Adaptive Design 8.3        Regulatory Considerations   9          CLINICAL TRIAL ANALYSIS 9.1.       Chapter Overview 9.2.       Methodology 9.3.       Cancer Biomarkers: List of Clinical Trials 9.4.       Clinical Trial Analysis: TMB 9.4.1.    Analysis by Trial Registration Year 9.4.2.    Analysis by Trial Recruitment Status 9.4.3.    Analysis by Trial Phase 9.4.4.    Analysis by Trial Design 9.4.5.    Analysis by Disease Indication 9.4.6.    Most Active Players 9.4.7.    Analysis by Number of Clinical Trials and Geography 9.4.8.    Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status 9.4.9.    Analysis by Enrolled Patient Population and Geography 9.4.10.  Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status   9.5.       Clinical Trial Analysis: MSI / MMR 9.5.1.    Analysis by Trial Registration Year 9.5.2.    Analysis by Trial Recruitment Status 9.5.3.    Analysis by Trial Phase 9.5.4.    Analysis by Trial Design 9.5.5.    Analysis by Disease Indication 9.5.6.    Most Active Players 9.5.7.    Analysis by Number of Clinical Trials and Geography 9.5.8.    Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status 9.5.9.    Analysis by Enrolled Patient Population and Geography 9.5.10.  Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status   9.6.       Clinical Trial Analysis: TILs 9.6.1.    Analysis by Trial Registration Year 9.6.2.    Analysis by Trial Recruitment Status 9.6.3.    Analysis by Trial Phase 9.6.4.    Analysis by Trial Design 9.6.5.    Analysis by Disease Indication 9.6.6.    Most Active Players 9.6.7.    Analysis by Number of Clinical Trials and Geography 9.6.8.    Analysis by Number of Clinical Trials, Trial Phase and Recruitment Status 9.6.9.    Analysis by Enrolled Patient Population and Geography 9.6.10.  Analysis by Enrolled Patient Population, Trial Phase and Recruitment Status   9.7        Clinical Trials Summary: Analysis by Registration Year and Biomarker 9.8        Clinical Trials Summary: Analysis by Registration Year and Disease Indication   10.1.     Chapter Overview 10.2.     Assumptions 10.3      Forecast Methodology 10.4.     Global Cancer Biomarkers Testing Market, 2019-2030 (By Value) 10.5.     Global Cancer Biomarkers Testing Market, 2019-2030 (By Volume) 10.6.     Cancer Biomarkers Testing Market: Distribution by Geography, 2019-2030 (By Value) 10.7.     Cancer Biomarkers Testing Market: Distribution by Geography, 2019-2030 (By Volume) 10.8.     Cancer Biomarkers Testing Market: Distribution by Type of Test, 2019-2030 (By Value) 10.8.1.  Cancer Biomarkers Testing Market: Distribution by Type of test and Geography, 2019-2030 (By Value) 10.9.     Cancer Biomarkers Testing Market: Distribution by Type of test, 2019-2030 (By Volume) 10.9.1.  Cancer Biomarkers Testing Market: Distribution by Type of test and Geography, 2019-2030 (By Volume) 10.10.   Cancer Biomarkers Testing Market: Distribution by Disease Indication, 2019-2030 (By Value) 10.11.   Cancer Biomarkers Testing Market:  Distribution by Disease Indication, 2019-2030 (By Volume) 10.12.   Cancer Biomarkers Testing Market:  Distribution by Analytical Technique, 2019-2030 (By Value) 10.12.1.
Cancer Biomarkers Testing Market: Distribution by Analytical Technique and Geography, 2019-        2030 (By Value) 10.13.   Cancer Biomarkers Testing Market: Distribution by Analytical Technique, 2019-2030 (By Volume) 10.13.1. Cancer Biomarkers Testing Market: Distribution by Analytical Technique and Geography, 2019-2030 (By Volume) 10.14.   Cancer Biomarkers Testing Market: Distribution by Biomarker, 2019-2030 (By Value) 10.15.   Cancer Biomarkers Testing Market for TMB, 2019-2030 (By Value) 10.15.1.
Cancer Biomarkers Testing Market for TMB: Distribution by Geography, 2019-2030 (By Value) 10.15.2. Cancer Biomarkers Testing Market for TMB: Distribution by Cancer Indication, 2019-2030 (By Value) 10.15.3.
Cancer Biomarkers Testing Market for TMB: Distribution by Analytical Technique, 2019-2030 (By Value) 10.15.4. Cancer Biomarkers Testing Market for TMB: Distribution by Type of test, 2019-2030 (By Value) 10.16.   Cancer Biomarkers Testing Market for MSI / MMR, 2019-2030 (By Value) 10.16.1.
Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Geography, 2019-2030 (By Value) 10.16.2. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Cancer Indication, 2019-2030 (By Value) 10.16.3.
Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Analytical Technique, 2019-2030 (By Value) 10.16.4. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Type of test, 2019-2030 (By Value) 10.17.   Cancer Biomarkers Testing Market for TILs, 2019-2030 (By Value) 10.17.1.
Cancer Biomarkers Testing Market for TILs: Distribution by Geography, 2019-2030 (By Value) 10.17.2. Cancer Biomarkers Testing Market for TILs: Distribution by Cancer Indication, 2019-2030 (By Value) 10.17.3.
Cancer Biomarkers Testing Market for TILs: Distribution by Analytical Technique, 2019-2030 (By Value) 10.17.4. Cancer Biomarkers Testing Market for TILs: Distribution by Type of test, 2019-2030 (By Value) 10.18.   Cancer Biomarkers Testing Market: Distribution by Biomarker, 2019-2030 (By Volume) 10.19.   Cancer Biomarkers Testing Market for TMB, 2019-2030 (By Volume) 10.19.1.
Cancer Biomarkers Testing Market for TMB: Distribution by Geography, 2019-2030 (By Volume) 10.19.2. Cancer Biomarkers Testing Market for TMB: Distribution by Cancer Indication, 2019-2030 (By Volume) 10.19.3.
Cancer Biomarkers Testing Market for TMB: Distribution by Analytical Technique, 2019-2030 (By Volume) 10.19.4. Cancer Biomarkers Testing Market for TMB: Distribution by Type of test, 2019-2030 (By Volume) 10.20.   Cancer Biomarkers Testing Market for MSI / MMR, 2019-2030 (By Volume) 10.20.1.
Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Geography, 2019-2030 (By Volume) 10.20.2. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Cancer Indication, 2019-2030 (By Volume) 10.20.3.
Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Analytical Technique, 2019-2030 (By Volume) 10.20.4. Cancer Biomarkers Testing Market for MSI / MMR: Distribution by Type of test, 2019-2030 (By Volume) 10.21.   Cancer Biomarkers Testing Market for TILs, 2019-2030 (By Volume) 10.21.1.
Cancer Biomarkers Testing Market for TILs: Distribution by Geography, 2019-2030 (By Volume) 10.21.2. Cancer Biomarkers Testing Market for TILs: Distribution by Cancer Indication, 2019-2030 (By Volume) 10.21.3.
Cancer Biomarkers Testing Market for TILs: Distribution by Analytical Technique, 2019-2030 (By Value) 10.21.4. Cancer Biomarkers Testing Market for TILs: Distribution by Type of Test, 2019-2030 (By Value)   11.1.     Chapter Overview 11.1.1.  Increasing Focus on Precision Medicine 11.1.2.  Rise in Number of Biomarker-based Clinical Trials 11.1.3.  Emerging Technologies for Biomarker Assessment 11.1.4.  Development of Companion Diagnostic Products 11.1.5.  Other Opportunities   12.1.     Chapter Overview 12.2.     Companion Diagnostics: Needs of Different Stakeholders 12.3.     Comparison of Needs of Various Stakeholders 12.3.1.  Needs of Drug Developers 12.3.2.  Needs of Companion Diagnostics Developers 12.3.3.  Needs of Regulatory Authorities 12.3.4.  Needs of Testing Laboratories 12.3.5.  Needs of Payers / Insurance Providers 12.3.6.  Needs of Physicians 12.3.7.  Needs of Patients   13.1.     Chapter Overview 13.2.     Companion Diagnostics: Components of the Value Chain 13.3.     Companion Diagnostics Value Chain: Cost Distribution 13.3.1.  Companion Diagnostics Value Chain: Costs Associated with Research and Product Development 13.3.2.  Companion Diagnostics Value Chain: Costs Associated with Costs Associated with Manufacturing and Assembly 13.3.3.  Companion Diagnostics Value Chain: Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks 13.3.4.  Companion Diagnostics Value Chain: Costs Associated with Payer Negotiation and KoL Engagement 13.3.5.  Companion Diagnostics Value Chain: Costs Associated with Marketing and Sales   14.1.     Chapter Overview 14.2.     Methodology 14.3.     Clinical Trial Analysis 14.3.1.  List of Likely Drug Candidates for IVD Developers 14.4.     Cumulative Distribution of Biomarker-based Trials by Registration Year, 2016-2019 14.4.1.  Analysis of Biomarker-based Trials of Most Popular Biomarkers 14.4.2.  Analysis of Biomarker-based Trials of Moderately Popular Biomarkers 14.4.3.  Analysis of Biomarker-based Trials of Less Popular / Other Biomarkers 14.4.4.  Word Cloud of Other Emerging Biomarkers   14.4.5.  Cumulative Distribution of Trials by Registration year and Most Popular Biomarkers 14.4.6.  Cumulative Distribution of Trials by Registration year and Moderately Popular Biomarkers 14.4.7.  Cumulative Distribution of Trials by Registration year and Less Popular / Other Biomarkers 14.5.     Distribution of Biomarker-based Trials by Most Popular Indications 14.5.1.  Distribution of Biomarker-based Trials by Moderately Popular Indications 14.5.2.  Distribution of Biomarker-based Trials by Less Popular / Other Indications 14.5.3.  Word Cloud of Other Emerging Indications in Biomarker-based Clinical Trials 14.5.4.  Cumulative Distribution of Trials by Registration year and Most Popular Indication 14.5.5.  Cumulative Distribution of Trials by Registration year and Moderately Popular Indications 14.5.6.  Cumulative Distribution of Trials by Registration year and Less Popular / Other Indications 14.6.     Analysis of Biomarker-based Trials by Phase of Development 14.6.1.  Analysis of Biomarker-based Trials by Phase of Development and Most Popular Biomarkers 14.6.2.  Analysis of Biomarker-based Trials by Phase of Development and Moderately Popular Biomarkers 14.6.3.  Analysis of Biomarker-based Trials by Phase of Development and Less Popular and Other Biomarkers 14.6.4.  Analysis of Biomarker-based Trials by Phase of Development and Most Popular Indications 14.6.5.  Analysis of Biomarker-based Trials by Phase of Development and Moderately Popular Indications 14.6.6.  Analysis of Biomarker-based Trials by Phase of Development and Less Popular and Other Indications 14.7.     Analysis of Biomarker-based Trials by Sponsor 14.7.1.  Analysis of Biomarker-based Trials by Sponsor and Most Popular Biomarkers 14.7.2.  Analysis of Biomarker-based Trials by Sponsor and Moderately Popular Biomarkers 14.7.3.  Analysis of Biomarker-based Trials by Sponsor and Most Popular Indications 14.7.4.  Analysis of Biomarker-based Trials by Sponsor and Moderately Popular Indications 14.8.     Analysis of Biomarker-based Trials by Recruitment Status 14.9.     Analysis of Biomarker-based Trials by Therapy Design 14.10.   Analysis of Biomarker-based Trials by Geography 14.10.1.
Analysis of Biomarker-based Trials by Trial Phase and Recruitment Status 14.11.   Clinical Trials Summary: Analysis by Biomarker and Most Popular Indications 14.12.   Clinical Trials Summary: Analysis by Biomarker and Moderately Popular Indications 14.13.   Clinical Trials Summary: Analysis by Biomarker and Other Emerging Indications   Contact Details Gaurav Chaudhary +1 (415) 800 3415 [email protected] Source: Free Articles from ArticlesFactory.com .

Top blog stories

A review of Idmobile.com

Idmobile.com offers both pay-as-you-go and contract plans. Pay-as-you-go plans are ideal for customers who don't want to be tied down to a long-term contract, and they can purchase bundles of data, minutes, and texts as and when they need them.

see post

A review of Idmobile.com

Idmobile.com offers both pay-as-you-go and contract plans. Pay-as-you-go plans are ideal for customers who don't want to be tied down to a long-term contract, and they can purchase bundles of data, minutes, and texts as and when they need them.

see post

AO.co: Online Shopping Made Simple

AO.co is a trusted expert in TVs, washing machines, clothes dryers and other household appliances. AO.com is one of the largest retailers in the UK and it specializes in electronics, clothes and home furniture.

see post

For our people.

At Three, we believe phones are good. They just make life better. Easier. And more fun. But we all need to find a balance that works for us. Our mission is to help our customers use their phones to live their best lives.

see post

We make your life easier

We make your life easier Since 1992, we’ve been helping customers get the best deal on their dream phone. We firmly believe in giving you the highest quality, for the lowest price. That’s why we work with three of the UK’s leading networks to do all the haggling for you,...

see post

FOUR BRANDS BECOME ONE. CURRYS.

Currys PLC is a leading omnichannel retailer of technology products and services, operating through 800+ stores and 16 websites in seven countries.

see post

Halfords - Quicker, Easier, and Convenient.

At Halfords, we're all about the journey. With more than 700 stores with over 10,000 colleagues, we're the UK's leading retailer of automotive and cycling products. We are also the leading operator in MOT, tyres, car servicing and car repairs - pleasing more than 750,000 customers every year.

see post

FOUR BRANDS BECOME ONE. CURRYS.

Currys PLC is a leading omnichannel retailer of technology products and services, operating through 800+ stores and 16 websites in seven countries.

see post

Sky - Epic. Endless. Entertainment.

It's important to us that everyone gets great customer service and can enjoy our products, no matter their level of sight. So, if you're blind, partially sighted or struggle to see or read the screen, we’ve a range of features to help you get the most from our products and...

see post

Nasty Gal - We exist for the “girl in progress”.

Look iconic, without the hassle— using Nasty Gal discount codes, you can shop your favorite pieces for way less by simply entering one of our promotional codes (of your choice) at the checkout. From delivery offers, to promo deals, we keep ‘em coming, so you always have the offer you...

see post

Digital Publishing From Past to Now

The Covid-19 has caused the school and universities to shut down around the world creating a major issue in Learning and Education. As this virus spreads through the interaction and if social distanci... The Covid-19 has caused the school and universities to shut down around the world creating a major...

see post

Why it’s Important to Manage Your Holiday Calendars?

A printable calendar 2021 is a prominent online platform where you download printable calendars of your choice. These calendars can be customized as per our client requirement with photo, text, logo, or any other image. If you are thinking of planning a dream vacation tour with family and kids but...

see post

The German People Is A Genius Not A Superior One

The world hasn’t forgotten the Superiority of the German People theory adopted by Hitler and resulting in massive destruction represented in the killing of millions of people and the destruction... The world hasn’t forgotten the Superiority of the German People theory adopted by Hitler and resulting in massive destruction represented...

Will EU Remain Spectators in Arms Race?

Emmaneul Macron, the youngest president in French history and the youngest French head of state since Napoleon, has said: ‘In the absence of a legal framework, they (EU member states) could rapi... Emmaneul Macron, the youngest president in French history and the youngest French head of state since Napoleon, has...

The Characteristics of the Dictators

1-The dictator believes that all his opinions are always right. 2-The dictator believes that he is the embodiment of the country. Any kind of opposition against him is considered a crime against the ... 1-The dictator believes that all his opinions are always right. 2-The dictator believes that he is...

Why is Getting My Dog Groomed So Expensive?

We know the importance of getting our dogs groomed. But not all of us can actually afford the grooming of our dogs luxury pet centre.   We know the importance of getting our dogs groomed. But not all of us can actually afford the grooming of our dogs luxury pet centre....

Dog Sitting Services - How a Professional Dog Sitter Gives You Peace of Mind

You need to travel, or you are traveling frequently. What are you doing with your pets or your beloved dog? You can’t take your dog with you when you are traveling.    You need to travel, or you are traveling frequently. What are you doing with your pets or your beloved...

How Can I Train a Dog at Home

This article teaches you how to train a dog at home. You can toilet train her at home. You can also train her in removing unwanted behaviours and many exciting tricks. You can train a dog anywhere. So, how can I train a dog at home ? In fact, most...

Reasons why grooming your dog is good for you and the dog

Having a dog is great but comes with a lot of responsibilities, just like having any other pet. The main responsibility is grooming the dog regularly, something that some people still question the importance of it. If you have been wondering whether you should be grooming your dog, then below...

Sterilization of Dogs - An Overview

Neutering (also known as castration) and spaying are the common term used to describe the surgical procedure during which both testicles (in males) and uterus and its parts (in females) are removed in order to sterilize (make infertile) a male and female dog respectively. At Pet Prime Veterinary Clinic (Dog...

Reasons Why Dogs Become Aggressive

You may have noticed cases of your dog suddenly showing signs of aggression or rather becoming aggressive and threatening to bite. Such nasty behaviours and signs of aggression by your dog may be frustrating Well, if you have no idea why your dog gets aggressive all over a sudden and...

Things You Need to Consider Before Adopting a Dog

The loyal nature of dogs makes them the perfect pets, whether you have a family or not. However, most of the time, people rush into adopting pets only to end up being overwhelmed with the responsibilities, which are physical, emotional, and psychological. If you have been considering adopting a pooch,...

Search topic

Things You Need to Consider Before Adopting a Dog

The loyal nature of dogs makes them the perfect pets, whether you have a family or not. However, most of the time, people rush into adopting pets only to end up being overwhelmed with the responsibilities, which are physical, emotional, and psychological. If you have been considering adopting a pooch,...

Learn more